Announced Fri, 25 Sept, 2026 · 08:35 IST
Biocon Malaysia gets MHRA approval for new insulin fill-finish unit
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-3.0%1-day move
₹386.40
prior close
₹387.50
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.2-0.1-0.1-0.7-3.0-2.4-4.2-4.1-4.3-6.8————
Up moveDown movePending
AI summary
Biocon received UK MHRA approval for its new drug product fill-finish unit for Semglee (insulin glargine) at its Malaysia insulin facility. This follows EMA (European) approval secured in July for the same line. The approvals allow Biocon to commercially supply biosimilar insulin to UK and European markets, expanding its global biosimilars footprint.
Likely market impact
UK and EU approvals enable commercial insulin supply from Malaysia, supporting revenue growth in the biosimilars business.